挪威对瑞典非转移性前列腺癌国家指南的看法。

IF 1.4 4区 医学 Q3 UROLOGY & NEPHROLOGY Scandinavian Journal of Urology Pub Date : 2022-08-01 Epub Date: 2022-07-11 DOI:10.1080/21681805.2022.2075923
Karol Axcrona, Sven Löffeler
{"title":"挪威对瑞典非转移性前列腺癌国家指南的看法。","authors":"Karol Axcrona, Sven Löffeler","doi":"10.1080/21681805.2022.2075923","DOIUrl":null,"url":null,"abstract":"Almost two decades ago, Wiking Månsson reviewed the state of urological guidelines in an editorial in European Urology titled ‘Evidence-Based Urology – A Utopia?’ [1]. In his article, he posed the question: How are we doing in urology? and provided the rather unflattering answer: Not that good. He lamented that ‘...most of what is published in the urological journals has low level of evidence and as a consequence, low grade of recommendation’. A lot has changed since Månsson voiced his dismay and the change has mostly been for the better. Today, urological guidelines are based on a large number of randomized clinical trials and high-quality register studies. We can, with considerable pride, state that prostate cancer researchers from Scandinavia, with Sweden often in the lead, have made decisive contributions to these improvements. The Scandinavian Prostate Cancer Group (SPCG) has been the incubator of the major Nordic randomized trials, with SPCG-4 and SPCG-7 as the most widely known trials [2,3]. Furthermore, the National Prostate Cancer Register, a Swedish population-based, clinical register, has generated multiple high impact publications [4,5]. Clinical cancer registers are cost-efficient tools to study the often decade-long prostate cancer disease trajectory. In Scandinavia in general and in Sweden in particular, there is a strong scientific environment that has enabled the creation of evidence-based urological cancer guidelines. Clinical guidelines are formulated according to standard procedure, based on a transparent methodology, discussed in professional panels including representatives from other relevant professions and patient organizations. Modern guidelines are largely based on clinical evidence, with prospective randomized control trials having the highest, and retrospective studies from single institutions having the lowest impact. Changes in guidelines can have major implications for patient management, organization of the health care system and on health care economy. However, due to the high level of evidence required for strong recommendations, changes are often slow in the coming. In Europe, most countries adhere to the European Urological Association (EAU) guidelines [6]. While the recommendations in the EAU Guidelines are based on strict rules, the implementation has to be flexible since the health care systems and ‘health care culture’ varies to a certain degree across Europe. In some European countries, urologists and oncologists have adopted EAU guidelines as their own guidelines, while in other countries national guidelines have been issued. In contrast to the EAU guidelines, National guidelines can be written to suit the specific requirements, opportunities and limitations of a national health care system. For the first time a summary of the Swedish prostate cancer guidelines is published in English by Bratt et al. in this issue of the Scandinavian Journal of Urology [7]. Why is it important guidelines written by Swedish urologists and oncologists are published in an international scientific journal? It is important for several reasons: First, despite universally available publications of randomized and other important clinical trials, the interpretation of the evidence presented in these trials can vary substantially. Publication ensures that the selection of studies and their interpretation in the formulation of the guidelines are transparent. Furthermore, publication of national guidelines in peerreviewed journals opens for scrutiny, scientific discussion and criticism which in turn may lead to improvements of both the national and possibly, by way of inspiration and reflection, international guidelines, thus, leading to the development of ‘collective intelligence’. The current Swedish guidelines contain inspiring innovations and some notable deviations from international guidelines. On the innovative side, we take notice that ongoing and relevant clinical trials are listed in the summary of","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Norwegian perspective on the Swedish national guidelines on prostate cancer for non-metastatic disease.\",\"authors\":\"Karol Axcrona, Sven Löffeler\",\"doi\":\"10.1080/21681805.2022.2075923\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Almost two decades ago, Wiking Månsson reviewed the state of urological guidelines in an editorial in European Urology titled ‘Evidence-Based Urology – A Utopia?’ [1]. In his article, he posed the question: How are we doing in urology? and provided the rather unflattering answer: Not that good. He lamented that ‘...most of what is published in the urological journals has low level of evidence and as a consequence, low grade of recommendation’. A lot has changed since Månsson voiced his dismay and the change has mostly been for the better. Today, urological guidelines are based on a large number of randomized clinical trials and high-quality register studies. We can, with considerable pride, state that prostate cancer researchers from Scandinavia, with Sweden often in the lead, have made decisive contributions to these improvements. The Scandinavian Prostate Cancer Group (SPCG) has been the incubator of the major Nordic randomized trials, with SPCG-4 and SPCG-7 as the most widely known trials [2,3]. Furthermore, the National Prostate Cancer Register, a Swedish population-based, clinical register, has generated multiple high impact publications [4,5]. Clinical cancer registers are cost-efficient tools to study the often decade-long prostate cancer disease trajectory. In Scandinavia in general and in Sweden in particular, there is a strong scientific environment that has enabled the creation of evidence-based urological cancer guidelines. Clinical guidelines are formulated according to standard procedure, based on a transparent methodology, discussed in professional panels including representatives from other relevant professions and patient organizations. Modern guidelines are largely based on clinical evidence, with prospective randomized control trials having the highest, and retrospective studies from single institutions having the lowest impact. Changes in guidelines can have major implications for patient management, organization of the health care system and on health care economy. However, due to the high level of evidence required for strong recommendations, changes are often slow in the coming. In Europe, most countries adhere to the European Urological Association (EAU) guidelines [6]. While the recommendations in the EAU Guidelines are based on strict rules, the implementation has to be flexible since the health care systems and ‘health care culture’ varies to a certain degree across Europe. In some European countries, urologists and oncologists have adopted EAU guidelines as their own guidelines, while in other countries national guidelines have been issued. In contrast to the EAU guidelines, National guidelines can be written to suit the specific requirements, opportunities and limitations of a national health care system. For the first time a summary of the Swedish prostate cancer guidelines is published in English by Bratt et al. in this issue of the Scandinavian Journal of Urology [7]. Why is it important guidelines written by Swedish urologists and oncologists are published in an international scientific journal? It is important for several reasons: First, despite universally available publications of randomized and other important clinical trials, the interpretation of the evidence presented in these trials can vary substantially. Publication ensures that the selection of studies and their interpretation in the formulation of the guidelines are transparent. Furthermore, publication of national guidelines in peerreviewed journals opens for scrutiny, scientific discussion and criticism which in turn may lead to improvements of both the national and possibly, by way of inspiration and reflection, international guidelines, thus, leading to the development of ‘collective intelligence’. The current Swedish guidelines contain inspiring innovations and some notable deviations from international guidelines. On the innovative side, we take notice that ongoing and relevant clinical trials are listed in the summary of\",\"PeriodicalId\":21542,\"journal\":{\"name\":\"Scandinavian Journal of Urology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2022-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Scandinavian Journal of Urology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/21681805.2022.2075923\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/7/11 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian Journal of Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21681805.2022.2075923","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/7/11 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
A Norwegian perspective on the Swedish national guidelines on prostate cancer for non-metastatic disease.
Almost two decades ago, Wiking Månsson reviewed the state of urological guidelines in an editorial in European Urology titled ‘Evidence-Based Urology – A Utopia?’ [1]. In his article, he posed the question: How are we doing in urology? and provided the rather unflattering answer: Not that good. He lamented that ‘...most of what is published in the urological journals has low level of evidence and as a consequence, low grade of recommendation’. A lot has changed since Månsson voiced his dismay and the change has mostly been for the better. Today, urological guidelines are based on a large number of randomized clinical trials and high-quality register studies. We can, with considerable pride, state that prostate cancer researchers from Scandinavia, with Sweden often in the lead, have made decisive contributions to these improvements. The Scandinavian Prostate Cancer Group (SPCG) has been the incubator of the major Nordic randomized trials, with SPCG-4 and SPCG-7 as the most widely known trials [2,3]. Furthermore, the National Prostate Cancer Register, a Swedish population-based, clinical register, has generated multiple high impact publications [4,5]. Clinical cancer registers are cost-efficient tools to study the often decade-long prostate cancer disease trajectory. In Scandinavia in general and in Sweden in particular, there is a strong scientific environment that has enabled the creation of evidence-based urological cancer guidelines. Clinical guidelines are formulated according to standard procedure, based on a transparent methodology, discussed in professional panels including representatives from other relevant professions and patient organizations. Modern guidelines are largely based on clinical evidence, with prospective randomized control trials having the highest, and retrospective studies from single institutions having the lowest impact. Changes in guidelines can have major implications for patient management, organization of the health care system and on health care economy. However, due to the high level of evidence required for strong recommendations, changes are often slow in the coming. In Europe, most countries adhere to the European Urological Association (EAU) guidelines [6]. While the recommendations in the EAU Guidelines are based on strict rules, the implementation has to be flexible since the health care systems and ‘health care culture’ varies to a certain degree across Europe. In some European countries, urologists and oncologists have adopted EAU guidelines as their own guidelines, while in other countries national guidelines have been issued. In contrast to the EAU guidelines, National guidelines can be written to suit the specific requirements, opportunities and limitations of a national health care system. For the first time a summary of the Swedish prostate cancer guidelines is published in English by Bratt et al. in this issue of the Scandinavian Journal of Urology [7]. Why is it important guidelines written by Swedish urologists and oncologists are published in an international scientific journal? It is important for several reasons: First, despite universally available publications of randomized and other important clinical trials, the interpretation of the evidence presented in these trials can vary substantially. Publication ensures that the selection of studies and their interpretation in the formulation of the guidelines are transparent. Furthermore, publication of national guidelines in peerreviewed journals opens for scrutiny, scientific discussion and criticism which in turn may lead to improvements of both the national and possibly, by way of inspiration and reflection, international guidelines, thus, leading to the development of ‘collective intelligence’. The current Swedish guidelines contain inspiring innovations and some notable deviations from international guidelines. On the innovative side, we take notice that ongoing and relevant clinical trials are listed in the summary of
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Scandinavian Journal of Urology
Scandinavian Journal of Urology UROLOGY & NEPHROLOGY-
CiteScore
2.90
自引率
6.70%
发文量
70
期刊介绍: Scandinavian Journal of Urology is a journal for the clinical urologist and publishes papers within all fields in clinical urology. Experimental papers related to clinical questions are also invited.Important reports with great news value are published promptly.
期刊最新文献
Urinary stone assessment in a single-phase may replace the unenhanced and multiphase computed tomography protocol in painless visible haematuria. Diagnostic accuracy and safety of renal tumour biopsy in patients with small renal masses and its impact on treatment decisions. A population-based registry cohort study on the correlation between bladder-intact event-free survival and overall survival in cystectomy-ineligible/refusal muscle-invasive bladder cancer patients in Sweden. Minimising warm ischaemia time during robot-assisted partial nephrectomy. A video-based assessment of tumour excision, kidney reconstruction and intermediate time. Violation of onco-surgical principles is associated with survival outcomes in upper tract urothelial carcinomas after radical nephroureterectomy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1